Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.2
4.7
Journals
Biomedicines
Special Issues
Recent Advance in Prostate Cancer: From Diagnosis to Treatment
share announcement

Recent Advance in Prostate Cancer: From Diagnosis to Treatment

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cancer Biology and Oncology".

Deadline for manuscript submissions: closed (28 February 2023) | Viewed by 9129

Special Issue Editors

Dr. Alexander Winter

E-Mail Website
Guest Editor
University Hospital for Urology, Klinikum Oldenburg, Department of Human Medicine, School of Medicine and Health Sciences, Carl von Ossietzky University Oldenburg, 26129 Oldenburg, Germany
Interests: surgical management; (sentinel) lymph node surgery and diagnostics; epidemiology; prostate cancer; health services
Prof. Dr. Friedhelm Wawroschek

E-Mail Website
Guest Editor
University Hospital for Urology, Klinikum Oldenburg, Department for Human Medicine, School of Medicine and Health Sciences, Carl von Ossietzky University Oldenburg, Olden-burg, Germany
Interests: surgical management; (sentinel) lymph node surgery and diagnostics; epidemiology; prostate cancer; health services

Special Issue Information

Dear Colleagues,

In 2020, around 1.4 million new prostate cancer cases were recorded worldwide, accounting for 14% of all new cancer cases in men. Prostate cancer is the second most frequent cancer and the fifth leading cause of cancer death in men. Novel diagnostic strategies and therapeutic technologies will facilitate the development of forward-looking methods to diagnose and cure patients. This will have implications for improving tumor staging, surgical and radiotherapeutic techniques, and focal treatment strategies. Improved tumor detection and characterization will enable more targeted individualized treatment and reduce complications.

This Special Issue aims to explore novel technologies that are already in clinical use or may be able to transform current prostate cancer diagnostic and treatment pathways in the near future.

The use of artificial intelligence provides the ability to reduce the degree of subjectivity in imaging evaluation. There is a growing interest in the automatic extraction of quantitative features from medical images called radiomics. Used with new imaging techniques (e.g., PET/MRI), these strategies will improve diagnostics and enable more targeted therapy.

Likewise, the use of new (hybrid) tracers has also already facilitated a more targeted surgical approach or new ways of intraoperative navigation and has shown promising results.

Linked to novel markers, new risk-adapted personalized treatments for prostate cancer may emerge, from focal therapy to radiotherapy, high-precision surgery, and theragnostics.

In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following:

  • MRI;
  • PSMA hybrid imaging;
  • Fusion biopsy
  • New PET tracers;
  • Radiomics;
  • Machine learning;
  • Novel histopathological and molecular markers;
  • Augmented reality;
  • Intraoperative navigation;
  • Radio-, fluorescence-, and magnetometer-guided (lymph node) surgery;
  • Robotic surgery;
  • Radiotherapy;
  • Focal therapies;
  • Theragnostics.

Dr. Alexander Winter
Prof. Dr. Friedhelm Wawroschek
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • prostate cancer
  • prostate imaging
  • PSMA PET
  • fusion biopsy
  • radical prostatectomy
  • radiotherapy
  • focal therapy
  • theragnostics
  • molecular markers

Published Papers (4 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

8 pages, 866 KiB  
Communication
A Fluorescent and Magnetic Hybrid Tracer for Improved Sentinel Lymphadenectomy in Prostate Cancer Patients
by Svenja Engels, Bianca Michalik, Lena Dirks, Matthias N. van Oosterom, Friedhelm Wawroschek and Alexander Winter
Biomedicines 2023, 11(10), 2779; https://doi.org/10.3390/biomedicines11102779 - 13 Oct 2023
Cited by 1 | Viewed by 917
Abstract
In prostate cancer, sentinel lymph node dissection (sLND) offers a personalized procedure with staging ability which is at least equivalent to extended LND while inducing lower morbidity. A bimodal fluorescent–radioactive approach was introduced to improve sentinel LN (SLN) detection. We present the first [...] Read more.
In prostate cancer, sentinel lymph node dissection (sLND) offers a personalized procedure with staging ability which is at least equivalent to extended LND while inducing lower morbidity. A bimodal fluorescent–radioactive approach was introduced to improve sentinel LN (SLN) detection. We present the first in-human case series on exploring the use of a fluorescent–magnetic hybrid tracer in a radiation-free sLND procedure. Superparamagnetic iron oxide nanoparticles and indocyanine green were administered simultaneously in five prostate cancer patients scheduled for extended LND, sLND and radical prostatectomy. In situ and ex vivo fluorescence and magnetic signals were documented for each LN sample detected via a laparoscopic fluorescence imaging and magnetometer system. Fluorescence and magnetic activity could be detected in all patients. Overall, 19 lymph node spots could be detected in situ, 14 of which were fluorescently active and 18 of which were magnetically active. In two patients, no fluorescent LNs could be detected in situ. The separation of the LN samples resulted in a total number of 30 SLNs resected. Ex vivo measurements confirmed fluorescence in all but two magnetically active SLNs. One LN detected in situ with both modalities was subsequently shown to contain a metastasis. This study provides the first promising results of a bimodal, radiation-free sLND, combining the advantages of both the magnetic and fluorescence approaches. Full article
(This article belongs to the Special Issue Recent Advance in Prostate Cancer: From Diagnosis to Treatment)
►▼ Show Figures

Figure 1

9 pages, 824 KiB  
Communication
Postoperative Radiotherapy of Prostate Cancer: Adjuvant versus Early Salvage
by Daniel Wegener, Daniel M. Aebersold, Marc-Oliver Grimm, Peter Hammerer, Michael Froehner, Markus Graefen, Dirk Boehmer, Daniel Zips and Thomas Wiegel
Biomedicines 2022, 10(9), 2256; https://doi.org/10.3390/biomedicines10092256 - 12 Sep 2022
Cited by 1 | Viewed by 2046
Abstract
Results of three randomized clinical trials (RCTs) comparing adjuvant radiotherapy (ART) and early salvage radiotherapy (eSRT) of prostate carcinoma and a subsequent meta-analysis of the individual patient data from these RCTs were recently published. The results suggest that early eSRT is as effective [...] Read more.
Results of three randomized clinical trials (RCTs) comparing adjuvant radiotherapy (ART) and early salvage radiotherapy (eSRT) of prostate carcinoma and a subsequent meta-analysis of the individual patient data from these RCTs were recently published. The results suggest that early eSRT is as effective and potentially less toxic than ART. Therefore, eSRT should be considered the standard of care. However, due to limitations in the RCTs, ART remains a valid treatment option in patients with the combination of high-risk features such as Gleason Score (GS) 8–10, positive surgical margins (R1) and pathological T-stage 3 or 4 (pT3/4). This article provides a critical appraisal of the RCTs and the rationale for recommendations adopted in the current national guidelines regarding patients with high-risk features after radical prostatectomy (RP): ART should be offered in case of pT3/pT4 and R1 and Gleason Score 8–10; ART can be offered in case of pT3/pT4 and R0 and Gleason Score 8–10 as well as in case of multifocal R1 (including pT2) and Gleason Score 8–10. In any case, the alternative treatment option of eSRT in case of rising PSA should be discussed with the patient. Full article
(This article belongs to the Special Issue Recent Advance in Prostate Cancer: From Diagnosis to Treatment)
►▼ Show Figures

Figure 1

Review

Jump to: Research

14 pages, 700 KiB  
Review
Molecular Similarities and Differences between Canine Prostate Cancer and Human Prostate Cancer Variants
by Demitria M. Vasilatis, Christopher A. Lucchesi and Paramita M. Ghosh
Biomedicines 2023, 11(4), 1100; https://doi.org/10.3390/biomedicines11041100 - 5 Apr 2023
Cited by 1 | Viewed by 1874
Abstract
Dogs are one of few species that naturally develop prostate cancer (PCa), which clinically resembles aggressive, advanced PCa in humans. Moreover, PCa-tumor samples from dogs are often androgen receptor (AR)-negative and may enrich our understanding of AR-indifferent PCa in humans, a highly lethal [...] Read more.
Dogs are one of few species that naturally develop prostate cancer (PCa), which clinically resembles aggressive, advanced PCa in humans. Moreover, PCa-tumor samples from dogs are often androgen receptor (AR)-negative and may enrich our understanding of AR-indifferent PCa in humans, a highly lethal subset of PCa for which few treatment modalities are available This narrative review discusses the molecular similarities between dog PCa and specific human-PCa variants, underscoring the possibilities of using the dog as a novel pre-clinical animal model for human PCa, resulting in new therapies and diagnostics that may benefit both species. Full article
(This article belongs to the Special Issue Recent Advance in Prostate Cancer: From Diagnosis to Treatment)
►▼ Show Figures

Figure 1

21 pages, 1836 KiB  
Review
Oncolytic Adenovirus, a New Treatment Strategy for Prostate Cancer
by Kaiyi Yang, Shenghui Feng and Zhijun Luo
Biomedicines 2022, 10(12), 3262; https://doi.org/10.3390/biomedicines10123262 - 15 Dec 2022
Cited by 2 | Viewed by 3584
Abstract
Prostate cancer is the most common cancer and one of the leading causes of cancer mortality in males. Androgen-deprivation therapy (ADT) is an effective strategy to inhibit tumour growth at early stages. However, 10~50% of cases are estimated to progress to metastatic castration-resistant [...] Read more.
Prostate cancer is the most common cancer and one of the leading causes of cancer mortality in males. Androgen-deprivation therapy (ADT) is an effective strategy to inhibit tumour growth at early stages. However, 10~50% of cases are estimated to progress to metastatic castration-resistant prostate cancer (mCRPC) which currently lacks effective treatments. Clinically, salvage treatment measures, such as endocrine therapy and chemotherapy, are mostly used for advanced prostate cancer, but their clinical outcomes are not ideal. When the existing clinical therapeutic methods can no longer inhibit the development of advanced prostate cancer, human adenovirus (HAdV)-based gene therapy and viral therapy present promising effects. Pre-clinical studies have shown its powerful oncolytic effect, and clinical studies are ongoing to further verify its effect and safety in prostate cancer treatment. Targeting the prostate by HAdV alone or in combination with radiotherapy and chemotherapy sheds light on patients with castration-resistant and advanced prostate cancer. This review summarizes the advantages of oncolytic virus-mediated cancer therapy, strategies of HAdV modification, and existing preclinical and clinical investigations of HAdV-mediated gene therapy to further evaluate the potential of oncolytic adenovirus in prostate cancer treatment. Full article
(This article belongs to the Special Issue Recent Advance in Prostate Cancer: From Diagnosis to Treatment)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-4
Back to TopTop